'Suicide prevention baton made me feel less alone'
Samantha Southern, from Blackpool, who took part in the Baton of Hope tour in 2023, said it was the first time in years she had not felt alone and the event had brought her "connection".
Organised by the suicide prevention charity, bereaved families are preparing to carry the baton through 20 locations in the UK again in a bid to challenge stigma and campaign for practical change.
The 2025 tour begins in Blackpool in September.
The baton is carried like an Olympic torch, passed from person to person, being held by 100 local people who each have a direct connection to suicide.
Baton-bearers will walk through Blackpool, Fylde and Wyre. They will pass local services that can offer support for mental and physical health.
They will then tour the country, including visiting Leeds, London, Bournemouth and Jersey.
Mike McCarthy, co-founder of The Baton Of Hope, said: "The idea is that people who have been bereaved by suicide or survived a suicide attempt find some comfort by being involved."
Suicide is the biggest killer of men under the age of 50 in the UK, according to the Samaritans.
Mr McCarthy said he believed a change in strategy was needed.
"Suicide is preventable, he said. "Whatever we have been doing over the last twenty years hasn't worked."
He said he was motivated to start the charity after his son Ross took his own life.
"He wrote a long goodbye letter and one of the things that he said in that letter was please fight for mental health, the support is just not there," he said.
"If he could look down and see what we are trying to do in his name, and the name of all of the people we have lost to suicide, I'm sure he would think 'I'm proud of what you are trying to do'."
The campaign is being supported by the Blackpool-based Empowerment Charity, where Ms Southern is the Solace Suicide Prevention and Bereavement Manager.
Her husband Glen died in 2020 and she walked with the baton during the Baton of Hope tour in 2023.
"It was the first time in two-to-three years that I hadn't felt as alone," she said.
"Being with a community of people who just understood and got me. I think it brings connection."
Blackpool Councillor Jo Farrell, said: "It is an honour for Blackpool to host the launch of the Baton of Hope 2025 tour.
"This powerful movement shines a vital light on suicide awareness and reminds us that behind every statistic is a real person."
The 2025 tour sets off from the Village Hotel in Blackpool on Monday 1 September at 08.00 BST.
If you have been affected by any of the issues raised in this story you can visit BBC Action Line.
Listen to the best of BBC Radio Lancashire on Sounds and follow BBC Lancashire on Facebook, X and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230.
Suicide prevention tour to return for second year
Suicide baton relay participant wants to show hope
Suicide baton relay to inspire 'open conversations'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Lilly raises UK obesity shot price as Trump pressures pharma
(Bloomberg) — Eli Lilly & Co. is raising the list price for its obesity shot in the UK by as much as 170%, as the pharma industry comes under pressure from US President Donald Trump to increase medicine prices in Europe and lower them for Americans. The current list price in the UK for Lilly's Mounjaro ranges from £92 ($124.89) to £122 a month, depending on the dose. This will increase to between £133 and £330 from Sept. 1, with the US drugmaker saying it aims to bring rates in line with other countries. Trump sent letters to 17 of the world's largest drugmakers earlier this month, including Lilly and Novo Nordisk A/S, which makes the competing shot Wegovy, insisting they lower what they charge Medicaid in the US for existing drugs. He gave the companies 60 days to comply, saying he wants companies to negotiate harder with 'foreign freeloading nations' who pay less for their medicines. Lilly said the increase follows a review that looked to address pricing inconsistencies. The UK was one of the first countries where Mounjaro was introduced, with rates 'significantly below the European average to prevent delays' in availability via the National Health Service, the company added. 'With changes in the environment and new clinical evidence supporting the value of Mounjaro, Lilly are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation,' it said. Affordability Concerns The new list price is still well below the level in the US, where it costs over $1,000 a month. Still, the higher prices raised concerns in online forums from patients who say the drug will be unaffordable for them. Patients in the UK usually get most medicines on the National Health Service for a set prescription price of £9.90. However, obesity drugs have only just started to be rolled out on the NHS and the criteria for access are stringent. So far, the majority of patients who access the weight-loss shots have been doing so privately. The actual price that these patients pay is likely to be well below the list price, because Lilly negotiated commercial agreements with private providers. Still, those providers are likely to face difficult decisions on how much to pass on any price increase to patients. Pharmacies like Walgreens Boots Alliance Inc.'s Boots and Superdrug, as well as online providers like Juniper and Voy that have focused on weight-loss drugs, have benefited from the rush for obesity shots. If patients are unable to afford more expensive Mounjaro, they may also switch to Novo's Wegovy. Novo has not yet announced a similar increase in price for its obesity drug. While the list price has increased, Lilly said it is working with private providers to maintain access for patients. Separately, the company reached an agreement with the NHS to ensure continued supply and patient access. —With assistance from Madison Muller. (Updates with more detail on pharmacies selling the shots, from paragraph nine) ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Nootropics Market Size Projected to Attain USD 19.53 Billion by 2034
The global nootropics market is valued at USD 5.71 billion in 2025 and is projected to reach approximately USD 19.53 billion by 2034, expanding at a CAGR of 14.64% during the forecast period. Ottawa, Aug. 14, 2025 (GLOBE NEWSWIRE) -- According to a study published by Towards Healthcare, a sister firm of Precedence Research, the global nootropics market size was valued at USD 4.98 billion in 2024 and is projected to reach approximately USD 19.53 billion by 2034, growing at a CAGR of 14.64%. The industry's growth in recent years has been driven by rising awareness of mental health issues. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the market with the largest market share in 2024. Asia Pacific is anticipated to grow at the fastest rate in the nootropics market over the forecast period. By form, the capsules/tablets segment led the market in 2024. By form, the drinks segment is predicted to witness the fastest growth in the market over the forecast period. By distribution channel, the offline segment dominated the market in 2024. By distribution channel, the online segment is anticipated to grow at the fastest rate in the nootropics market during the forecast period. Market Overview & Potential The increased interest in brain health and mental performance is spearheading the industry growth in recent years. As the younger individuals are contributing significantly to the majorly in this industry by adopting these supplements for the increasing focus, mood, and creativity in the current period. Moreover, the products include ingredients like caffeine, ginseng. L-thenine is more popular in the industry nowadays. What are the Key Growth Drivers Involved in The Expansion of The Market? The rising need for cognitive enhancement among the working professional community is spearheading the industry growth in the current period. Moreover, the nootropic manufacturer are actively looking to create partnerships with the big corporate firms to lead their business in the current period. Furthermore, by providing several advantages such as improved memory, mental energy, and concentration to consumers, the nootropic supplements have gained immense industry attention in recent years. In December 2024, Cristiano Ronaldo invested $15 million in personalised nutrition company Bioniq, increasing the value of the company to $82 million. What Are the Emerging Trends Associated with the Market? The sudden shift towards plant-based and herbal nootropics has driven the industry growth in recent years. The rising popularity of functional beverages, such as drinks with brain-boosting ingredients, has contributed to the industry's growth in the past few years. You can place an order or ask any questions, please feel free to contact us at sales@ Regional Analysis How Did North America Dominate the Market in 2024? In 2024, North America led the nootropics market owing to the increased need for cognitive enhancement in the current period. Moreover, the market growth is mainly associated with factors such as the high awareness and acceptance of the mental wellness supplement in recent years in the region. Furthermore, the greater regulatory push has contributed immensely in the region, as per the recent regional survey. What Made the Asia Pacific Significantly Grow in the Market in 2024? In the nootropics market, the Asia Pacific is predicted to grow at the fastest CAGR during 2025-2034, akin to the rising mental awareness and the development of e-commerce platforms. Moreover, the regional countries such as India, China, and Japan are seen under the sophisticated growth in the wellness market in recent years. Furthermore, the younger population in the region is expected to drive the future growth of the industry, as they are seen as heavy adopters of nootropics for professional and academic performance. Segmental Insights By Form Analysis How did the Capsules and Tablets Segment Dominate the Market in 2024? The capsules and tablets segment held a major share of the nootropic market. Mainly, the segment is driven by its unique properties, such as the convenience, wide availability, and accurate dosage in the current period. Moreover, the individuals are actively seen preferring the tablet forms of the dosage due to traditional habits, which is driving the growth of the market in the present period, as per industry observation. How will the Drink Segment Expand Rapidly During 2025-2034? The drink segment is estimated to register rapid expansion during the forecast period due to its excellent characteristics like faster absorption, convenience, and on-the-go consumption facilities. Several nootropic ingredients, such as L-theanine, caffeine, and others, are actively seen in gaining immense attention from the younger generation, which is expected to lead the segment growth in the upcoming years. Moreover, factors such as the fast-paced and modern lifestyle are contributing to the segment's potential in the current phase. Become a valued research partner with us - By Distribution Channel, The offline segment dominated the market with the largest share in 2024. The offline channels, such as health stores, pharmacies, and supermarkets, remain key sales points for nootropics. These locations allow customers to get expert advice, see physical products, and make instant purchases. Many customers still prefer in-person purchases due to trust and habit. Retailers also offer bundled promotions and loyalty benefits, which boost foot traffic. The online segment is expected to grow at a significant rate due to increasing digital adoption, easy product comparison, and greater availability of global brands. E-commerce allows consumers to browse a wide range of nootropic supplements, read reviews, and access educational content before purchasing. Subscription models and influencer marketing have also accelerated growth. The convenience of doorstep delivery and targeted advertising helps brands connect with consumers more effectively. Recent Developments The first nootropics food lab in Canada was established in January 2025 by Raymond Thomas, a biology professor at Western University. The lab creates brain-boosting meals by fusing Western science with Indigenous dietary expertise. To promote brain health through functional meals, Thomas and his colleagues will develop novel dishes in collaboration with an in-house chef and utilize biochemistry and metabolomics to assess their cognitive effects. In February 2025, the Scientific Advisory Board and Research Snapshot sections were launched by Nootropics Depot to increase openness and confidence in the supplement sector. The new advisory board will supervise product formulations and study evaluations to guarantee the highest levels of safety and efficacy. It will include specialists in integrative medicine, fitness, plant biology, and ethnobotany. Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes schedule a call today: Nootropics Market Key Players Nootropics Depot Kimera Koffee Alternascript Cephalon LLC Teva Pharmaceuticals Onnit Powder City Mental Mojo Llc Mind Lab Pro Purelife Bioscience Company Ltd TruBrain Noocube Browse More Insights of Towards Healthcare: The global liquid biopsy IVD market was valued at US$ 2.21 billion in 2024 and is expected to reach US$ 2.54 billion in 2025. Projections indicate the market will grow to approximately US$ 8.72 billion by 2034, registering a CAGR of 14.79% during the forecast period. The liquid biopsy tube market stood at US$ 1.34 billion in 2024, rising to US$ 1.54 billion in 2025, and is anticipated to reach US$ 5.32 billion by 2034, expanding at a CAGR of 14.85% from 2025 to 2034. The specialty medical chairs market is valued at USD 5.12 billion in 2025 and is projected to climb to around USD 9.77 billion by 2034, growing at a CAGR of 7.43% over the forecast period. The biosensors market was valued at USD 30.04 billion in 2024, increasing to USD 32.64 billion in 2025, with expectations to reach USD 68.72 billion by 2034 at a CAGR of 8.64% from 2025 to 2034. The stem cell therapy market was worth USD 490 million in 2024, grew to USD 613.7 million in 2025, and is projected to reach around USD 4,777.40 million by 2034, expanding at a notable CAGR of 25.26% between 2025 and 2034. The home healthcare market is forecast to expand from USD 226.92 billion in 2025 to USD 476.80 billion by 2034, recording a CAGR of 8.6% over the analysis period. The regenerative medicine market is set to surge from USD 24.39 billion in 2025 to USD 139.70 billion by 2034, achieving a robust CAGR of 21.4%. The mice model market was valued at US$ 1.57 billion in 2024, increased to US$ 1.73 billion in 2025, and is expected to reach approximately US$ 4.1 billion by 2034, registering a CAGR of 10.04% during the forecast timeframe. The cancer biopsy market stood at US$ 30.81 billion in 2024, grew to US$ 36.61 billion in 2025, and is projected to soar to about US$ 163.29 billion by 2034, expanding at an impressive CAGR of 18.84% between 2025 and 2034. Meanwhile, the in vivo CAR-T platform market is gaining momentum worldwide, with expectations of generating hundreds of millions in revenue during the 2025–2034 period. Segments Covered in The Report By Form Capsules/Tablets Powder Drinks Others By Distribution Channel Offline Online By Region North America US Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Immediate Delivery Available | Buy This Premium Research @ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramErreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
39 minutes ago
- Yahoo
NHS Fife told to ‘progress corrective actions' urgently on single-sex spaces
NHS Fife has been told by the UK's equality watchdog to 'progress corrective actions without delay' regarding single-sex spaces after the health board admitted it failed to carry out an equality impact assessment previously. The Equality and Human Rights Commission (EHRC) wrote to NHS Fife regarding access to single-sex facilities for staff on February 21, after the employment tribunal brought by nurse Sandie Peggie against the health board adjourned. Ms Peggie was suspended after she complained about having to share a changing room with transgender medic Dr Beth Upton at Victoria Hospital in Kirkcaldy, Fife, on Christmas Eve 2023. She was placed on special leave after Dr Upton made an allegation of bullying and harassment, and cited concerns about 'patient care'. Ms Peggie has lodged a claim against NHS Fife and Dr Upton, citing the Equality Act 2010, including sexual harassment; harassment related to a protected belief; indirect discrimination; and victimisation, and the case has been adjourned until September. Baroness Kishwer Falkner, chairwoman of the EHRC, said NHS Fife previously admitted no equality impact assessment had been carried out and one is now expected around September 30, having been commissioned retrospectively. The EHRC recently directed NHS Fife to take 'corrective action' to ensure compliance with regulations which require public bodies to assess how policies and practices affect people with protected characteristics. On June 10, it held a meeting to reiterate that the Scottish Government has a duty to ensure public bodies comply, following the UK Supreme Court ruling in April that the terms 'woman' and 'sex' in the 2010 Equality Act 'refer to a biological woman and biological sex'. On July 23, NHS Fife 'assured the EHRC that it has taken steps in several areas, including a full review and audit of changing, toilet and locker room facilities', and it 'committed to ensuring there will be no delay in progressing all the compliance actions directed', according to the regulator. Baroness Falkner said the EHRC had 'urged NHS Fife to progress the corrective actions we directed without delay' to 'protect staff from discrimination and harassment'. Maya Forstater, chief executive of human rights charity Sex Matters, said: 'This directive to NHS Fife is an unprecedented intervention from the EHRC. 'While long overdue, this is a clear instruction to NHS Fife – and all employers – that it cannot get away with continuing to flout the Equality Act. 'There have been relentless efforts to undermine the Supreme Court judgment since it was handed down. 'This leads to women being subjected to bullying, harassment and discrimination if they stand up, as Sandie Peggie did, for their right to undress with dignity and privacy. 'The EHRC has the power to hold employers, service providers and public sector bodies to account.' The employment tribunal held further hearings in July before adjourning until September. Scottish Conservative equalities spokeswoman Tess White said: 'This damning directive from the EHRC confirms that on top of being negligent, incompetent and biased, NHS Fife broke the law in relation to the Sandie Peggie case. 'It's abundantly clear that the positions of the chief executive and senior health board colleagues are completely untenable. 'The shameful admission from the health board confirms that Sandie Peggie was hung out to dry from the very beginning, simply for standing up for her rights as a woman. Fairness and accountability must prevail. 'The First Minister must clear out those at the top of NHS Fife and finally demand that it, and all other public bodies, upholds the clear and unequivocal Supreme Court ruling entitling women to single-sex spaces.' Baroness Falkner said: 'The policies and practices of all Scottish health boards must comply with the Equality Act 2010. 'We will continue to engage with NHS Fife and monitor its progress and the outcome of the measures it has committed to taking, to ensure compliance with the Equality Act and Public Sector Equality Duty.' NHS Fife said it welcomes continued engagement and oversight from the EHRC. It said: 'We are committed to working constructively with the EHRC to provide assurance that we fully understand, and are meeting, our obligations under the Equality Act 2010 and the Public Sector Equality Duty. This includes considering the implications of the recent Supreme Court ruling and the EHRC's interim guidance. 'A comprehensive review and audit of our facilities has been completed, and an equality impact assessment is under way. This will be concluded and published by September 30, 2025. 'Our priority is to ensure that all NHS Fife policies and practices protect the rights of our staff and comply fully with equality legislation.' The Scottish Government has been contacted for comment.